Disitamab vedotin and camrelizumab achieved durable remission in a patient with metastatic gastric cancer
New treatment combination shows promise for gastric cancer with brain metastasis
This case report and literature review describes a single patient with HER2-low, MSS advanced gastric cancer and brain metastasis who achiev…
A new combination of radiation and targeted therapies may help patients with advanced gastric cancer and brain metastasis achieve long-term …
ICIs Boost pCR in Early Triple-Negative Breast Cancer
Immune drugs combined with chemotherapy improve results for triple-negative breast cancer
Adding immune checkpoint inhibitors to chemotherapy improves pathological complete response in early triple-negative breast cancer, with PD-…
Adding immune checkpoint inhibitors to chemotherapy significantly increases the chance of clearing cancer cells in triple-negative breast ca…
Camrelizumab and apatinib show higher response rates and survival in treatment-naive patients with ESCC
Treatment Naive Patients Show Better Survival with Camrelizumab and Apatinib
This meta-analysis evaluates the efficacy of camrelizumab plus apatinib for advanced or metastatic esophageal squamous cell carcinoma. The a…
Patients with advanced esophageal cancer who have not had prior treatment may see better survival rates when using a combination of camreliz…
Second-line immunotherapy combination with etoposide and capecitabine improves extracranial disease control in pulmonary choriocarcinoma
New treatment combinations show promise for rare lung cancer
This systematic review and case report analyze 45 cases of primary pulmonary choriocarcinoma. A second-line combination of camrelizumab, eto…
A new combination of immunotherapy and chemotherapy may help control the spread of a rare type of lung cancer called pulmonary choriocarcino…
PD-1 inhibitors plus chemotherapy achieve 64% objective response rate in recurrent or metastatic nasopharyngeal carcinoma
Different PD-1 Inhibitors Show Varying Results for Nasopharyngeal Cancer
This systematic review and meta-analysis of 1,459 patients with recurrent or metastatic nasopharyngeal carcinoma found a pooled objective re…
A review of 1,459 patients shows that different PD-1 inhibitors combined with chemotherapy offer varying survival and response rates for nas…
Immune-based combinations show superior overall survival compared to sorafenib in advanced hepatocellular carcinoma
New data shows better survival for liver cancer patients
This systematic review and network meta-analysis of 8,138 patients evaluated immune-based combinations versus monotherapies for advanced hep…
New research highlights how specific immune-based drug combinations can improve survival rates for people with advanced liver cancer.
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
Immunotherapy Outperforms Standard Care for Advanced Liver Cancer
This Bayesian network meta-analysis of 7,301 patients with advanced hepatocellular carcinoma synthesized evidence from randomized trials. It…
A new analysis of 10 clinical trials shows that immunotherapy drugs help people with advanced liver cancer live longer than standard treatme…
Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
Sintilimab May Be Safer Lung Cancer Treatment
This retrospective cohort study evaluated 409 patients with stage IIIB-IV non-small cell lung cancer receiving PD-1 inhibitors.
One lung cancer drug may cause fewer serious side effects than others while working just as well, a real-world study suggests.
Camrelizumab plus nab-paclitaxel showed modest activity in previously treated advanced urothelial carcinoma patients
New Treatment Extends Life for Bladder Cancer Patients
This multicenter Phase II study evaluated camrelizumab plus nab-paclitaxel in 60 patients with advanced urothelial carcinoma who progressed …
For years, Mark, 64, thought he’d beaten cancer.
Neoadjuvant Chemoimmunotherapy Alters Tumor Microenvironment in Esophageal Cancer
Combination therapy may help overcome resistance in esophageal cancer
This Phase 3 RCT in 55 patients with locally advanced esophageal squamous cell carcinoma compared neoadjuvant chemotherapy alone versus comb…
A small trial suggests combination therapy might help overcome resistance in esophageal cancer by targeting specific immune cells.
TACE plus donafenib and camrelizumab shows improved outcomes in unresectable hepatocellular carcinoma
Liver Cancer Patients May Live Twice as Long With New Combo
This single-center retrospective cohort study compared TACE plus donafenib and camrelizumab to TACE plus donafenib alone in 116 patients wit…
A new combination therapy could nearly double survival time for advanced liver cancer patients.
TACE plus camrelizumab and rivoceranib prolongs progression-free survival versus TACE alone in unresectable HCC
Combination therapy extends time without cancer progression in liver cancer patients
This phase II randomized trial in 200 patients with unresectable hepatocellular carcinoma compared TACE plus camrelizumab and rivoceranib (T…
Adding two new drugs to standard liver cancer treatment helped patients go 10.8 months longer without their cancer getting worse compared to…
All camrelizumab Articles
- Disitamab vedotin and camrelizumab achieved durable remission in a patient with metastatic gastric cancer
- ICIs Boost pCR in Early Triple-Negative Breast Cancer
- Camrelizumab and apatinib show higher response rates and survival in treatment-naive patients with ESCC
- Second-line immunotherapy combination with etoposide and capecitabine improves extracranial disease control in pulmonary choriocarcinoma
- PD-1 inhibitors plus chemotherapy achieve 64% objective response rate in recurrent or metastatic nasopharyngeal carcinoma
- Immune-based combinations show superior overall survival compared to sorafenib in advanced hepatocellular carcinoma
- Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
- Camrelizumab Associated With Higher Progression Risk Versus Pembrolizumab in Nonsquamous NSCLC Cohort
- Camrelizumab plus nab-paclitaxel showed modest activity in previously treated advanced urothelial carcinoma patients
- Neoadjuvant Chemoimmunotherapy Alters Tumor Microenvironment in Esophageal Cancer
- TACE plus donafenib and camrelizumab shows improved outcomes in unresectable hepatocellular carcinoma
- TACE plus camrelizumab and rivoceranib prolongs progression-free survival versus TACE alone in unresectable HCC
- SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients
- Guideline reviews perioperative immunotherapy for hepatocellular carcinoma after resection or ablation